Polymyxin combinations: Pharmacokinetics and pharmacodynamics for rationale use

Pharmacotherapy

Volumn 35, Issue 1, 2015, Pages 34-42

  Bergen, Phillip J ^a   Bulman, Zackery P ^b   Saju, Sarith ^b   Bulitta, Juergen B ^b   Landersdorfer, Cornelia ^b   Forrest, Alan ^b   Li, Jian ^b   Nation, Roger L ^b   Tsuji, Brian T ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Colistin; Colistin methanesulfonate; Combination; Polymyxin B; Polymyxins

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; COLISTIMETHATE; COLISTIN; DORIPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG MEGADOSE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INOCULATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SALVAGE THERAPY; SERRATIA MARCESCENS; VENTILATOR ASSOCIATED PNEUMONIA; COMBINATION DRUG THERAPY; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXINS; TREATMENT OUTCOME;

EID: 84940737443     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1537     Document Type: Article

References (51)

1. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
2. Yow EM, Moyer JH. Toxicity of polymyxin B. II. Human studies with particular reference to evaluation of renal function. AMA Arch Intern Med 1953;92:248-57.
3. Walker B, Barrett S, Polasky S, et al. Environment. Looming global-scale failures and missing institutions. Science 2009;325:1345-6.
4. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva, Switzerland: World Health Organization; 2014.
5. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
6. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013;57:524-31.
7. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008;61:636-42.
8. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-9.
9. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(Suppl 2):S95-9.
10. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE 2012;7:e52349.
11. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013;59:225-31.
12. Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with gram-negative bacteria. Antimicrob Agents Chemother 2014;58:851-8.
13. Morelli P, Ferrario A, Tordato F, Piazza A, Casari E. Successful treatment of post-neurosurgical multidrug-resistant Pseudomonas aeruginosa meningo-encephalitis with combination therapy of colistin, rifampicin and doripenem. J Antimicrob Chemother 2014;69:857-9.
14. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349-58.
15. Ceccarelli G, Falcone M, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:2900-1.
16. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013;141:1214-22.
17. Batirel A, Balkan II, Karabay O, et al. Comparison of colistincarbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311-22.
18. Moore NM, Flaws ML. Treatment strategies and recommendations for Pseudomonas aeruginosa infections. Clin Lab Sci 2011;24:52-6.
19. Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of "old" polymyxins: what is new? Diagn Microbiol Infect Dis 2012;74:213-23.
20. Bergen PJ, Forrest A, Bulitta JB, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrugresistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011;55:5134-42.
21. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:333-6.
22. Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 2010;67:191-7.
23. Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011;70:246-52.
24. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007;30:537-40.
25. Urban C, Mariano N, Rahal JJ. In Vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against Multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010;54:2732-4.
26. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:5316-22.
27. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047-51.
28. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007;45:594-8.
29. Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011;37:244-7.
30. Clancy CJ, Chen L, Hong JH, et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 2013;57:5258-65.
31. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009;53:2133-5.
32. Tangden T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014;58:1757-62.
33. Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011;55:5685-95.
34. Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013;57:3738-45.
35. Deris ZZ, Yu HH, Davis K, et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012;56:5103-12.
36. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 2009;53:3430-6.
37. Lora-Tamayo J, Murillo O, Bergen PJ, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother 2014;69:2434-42.
38. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56:2108-13.
39. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17:1798-803.
40. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50.
41. Dubrovskaya Y, Chen TY, Scipione MR, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2013;57:5394-7.
42. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-60.
43. Furtado GHC, d'Azevedo PA, Santos AF, Gales AC, Pignatari ACC, Medeiros EAS. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30:315-9.
44. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extendedinterval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720-6.
45. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51.
46. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9.
47. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010;65:2231-7.
48. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008;32:450-4.
49. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxinonly-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:596-9.
50. Tsioutis C, Kritsotakis EI, Maraki S, Gikas A. Infections by pandrug-resistant gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients. Eur J Clin Microbiol Infect Dis 2010;29:301-5.
51. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90.